erlotinib hydrochloride has been researched along with Endometrial Neoplasms in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Bakır, E; Cumaoğlu, A; Eken, A; Hamurcu, Z; Karaca, B; Yerer, MB | 1 |
| Ikeda, S; Kigure, K; Minegishi, T; Nakamura, K; Nishimura, T; Yamashita, S | 1 |
| Biagi, J; Cutz, JC; Dancey, J; Dore, N; Eisenhauer, EA; Elit, L; Fyles, A; Ghatage, P; Hoskins, PJ; Mazurka, J; Oza, AM; Provencher, D; Sakurada, A; Tsao, MS | 1 |
1 trial(s) available for erlotinib hydrochloride and Endometrial Neoplasms
| Article | Year |
|---|---|
Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Adenosquamous; Endometrial Neoplasms; Erlotinib Hydrochloride; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Quinazolines | 2008 |
2 other study(ies) available for erlotinib hydrochloride and Endometrial Neoplasms
| Article | Year |
|---|---|
Doxazosin and erlotinib have anticancer effects in the endometrial cancer cell and important roles in ERα and Wnt/β-catenin signaling pathways.
Topics: Antineoplastic Agents; beta Catenin; Doxazosin; Endometrial Neoplasms; Erlotinib Hydrochloride; Estrogen Receptor alpha; Female; Humans; Wnt Signaling Pathway | 2021 |
Effect of the molecular targeted drug, erlotinib, against endometrial cancer expressing high levels of epidermal growth factor receptor.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Carcinoma, Endometrioid; Endometrial Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Immunohistochemistry; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Targeted Therapy; Reverse Transcriptase Polymerase Chain Reaction; RNA, Small Interfering; Transfection; Xenograft Model Antitumor Assays | 2015 |